Comparative Pharmacology
Head-to-head clinical analysis: UNITUXIN versus UNLOXCYT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNITUXIN versus UNLOXCYT.
UNITUXIN vs UNLOXCYT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dinutuximab is a chimeric monoclonal antibody that binds to the disialoganglioside GD2, which is overexpressed on neuroblastoma cells. Binding to GD2 induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
UNLOXCYT (pexidartinib) is a small-molecule tyrosine kinase inhibitor that inhibits colony-stimulating factor 1 receptor (CSF1R), KIT proto-oncogene receptor tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring internal tandem duplication mutations. It also inhibits platelet-derived growth factor receptor alpha (PDGFRA) and beta (PDGFRB). Inhibition of CSF1R reduces the survival and function of tumor-associated macrophages, which play a role in tenosynovial giant cell tumor (TGCT) pathogenesis.
1,500 mg/m² intravenously over 1 hour on days 1, 8, and 15 of each 28-day cycle.
2 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal half-life approximately 22.6 days (range 11.4–45.3 days) in pediatric patients; supports every-other-week dosing. Half-life is prolonged compared to adults due to slower clearance in children.
Terminal elimination half-life is 12 hours (range 10-14 hours); steady-state achieved in approximately 2 days.
Unchanged drug: negligible renal excretion; metabolism and biliary/fecal elimination are the primary routes. Specific % not established; in clinical studies, <1% of dose recovered in urine as parent drug.
Primarily renal (70% unchanged), with 20% fecal via biliary elimination and 10% metabolized.
Category C
Category C
Monoclonal Antibody (CD20-directed)
Monoclonal Antibody (CD20-directed)